MK-1084, MK-3475A, CARBOPLATIN , PEMETREXED , MK-1084, CISPLATIN , Placebo for MK-1084
MK-1084-013
Phase 3 small_molecule active
Quick answer
MK-1084, MK-3475A, CARBOPLATIN , PEMETREXED , MK-1084, CISPLATIN , Placebo for MK-1084 for Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active